v3.25.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2025
Summary of Significant Accounting Policies  
Schedule of segment consolidated net loss, including significant segment expenses

The table below is a summary of the segment net loss, including significant segment expenses (in thousands):

THREE MONTHS ENDED JUNE 30, 

SIX MONTHS ENDED JUNE 30, 

2025

    

2024

    

2025

    

2024

Operating expenses:

  

  

  

  

Discovery research and development

$

26,244

$

9,995

$

48,031

$

20,392

Clinical research and development

23,149

9,304

40,306

17,696

Other research and development expenses

5,317

2,751

9,240

4,641

General and administrative

15,741

 

11,266

29,185

22,602

Total operating expenses

 

70,451

 

33,316

 

126,762

 

65,331

Loss from operations

 

(70,451)

 

(33,316)

 

(126,762)

 

(65,331)

Interest and other income, net

 

8,929

7,335

 

18,505

13,343

Loss before provision for income taxes

 

(61,522)

 

(25,981)

 

(108,257)

 

(51,988)

Provision for income taxes

 

139

53

 

237

82

Segment net loss and net loss attributable to ordinary shareholders

$

(61,661)

$

(26,034)

$

(108,494)

$

(52,070)